Evidence synthesis and HEOR
Evidence synthesis allows to bring together all relevant information on a research question
Value requires comparison but unfortunately, drug development decisions are usually made with in-depth quantitative analysis of internal data from the drug candidate and a comprehensive, but less quantitative, review of published data from other candidates. On top of it, single arm trials and comparison with placebo are very common. Meta-analyses can help here!
Evidence synthesis methodologies
PHARMAECONOMICA conducts state-of-the-art literature reviews and meta-analyses using the most rigorous methodologies, to ensure the reliability and reproducibility of the answers to your research questions.
High-quality literature reviews allow for an understanding of:
-
Disease patterns including etiology, definitions, and diagnosis
-
Epidemiologic, humanistic, and economic burden of the disease
-
Clinical Guidelines and patterns in clinical practice
-
Data and performance of the comparator treatments
-
Previous modeling exercises in the disease area
-
Inputs of the economic models on identification, measurement, and valuation of resource usage and utility estimates
We perform high-quality meta-analyses:
-
Pairwise meta-analysis (PMA): If the data from multiple trials are sufficiently homogenous, a pairwise meta-analysis can be performed to calculate pooled effect estimates. It involves groups of trials that compare the same two interventions directly (head-to-head)
-
Network meta-analysis (NMA): NMA combines trials with different treatments and comparators into a single framework and it permits to simultaneously accommodate direct and indirect comparisons. It also allows estimation of the ranking and hierarchy of interventions.
-
Model-based meta-analysis (MBMA):
-
MBMA incorporates parametric pharmacology models (e.g., with dose and
-
duration) and is able to integrate relevant pre-clinical, bio-marker, clinical safety and efficacy data of competing treatment options in a certain disease area.
Benefits of our evidence synthesis services
-
Product’s clinical differentiation
-
Prediction on how a new drug’s safety and efficacy profile might compare to the current SOC and other competitor drugs
-
Treatment comparisons even if no head-to-head trial available
-
Multi-treatment comparisons
-
Inform cost-effectiveness models (populate cost-effectiveness models)
-
Provide a ranking of the compared interventions for a particular outcome
-
Understanding of a drug’s dose-response relationship
-
Increase the probability of clinical trial success
-
MBMA has emerged as a methodology that quantifies clinical trial efficacy, tolerability, and safety information to enable strategic drug development decisions. It provides a quantitative framework for differentiation by allowing one to understand how a new compound will perform relative to existing relevant comparators and /or drugs in development
Modeling services for HTA submissions
To estimate both costs and consequences of alternative courses of action, models synthesize information on a range of variables such as natural history, clinical efficacy, health-related quality of life, resource use, and costs and results of these analytical models are used to decide which interventions represent good value for money from the perspective of a particular decision maker.
We can help if your Organization requires a model to:
-
Understand disease patterns and unmet needs
-
Support strategic planning
-
Develop an economic evaluation
-
Demonstrate value to inform payer decisions
Our experts use state-of-the-art methods to develop high-quality decision analytic models:
-
Decision trees
-
Markov and other stochastic process models
-
Simulations (individual patient, discrete event, etc.)
-
Infectious disease models
-
Statistical analyses (survival analysis, multivariate regression, utility data analysis, etc.)
-
Probabilistic, bivariate, univariate, and structural sensitivity analysis
-
The expected value of perfect information
-
Multi-criteria decision analysis
-
Time-driven activity-based costing
Benefits of economic modeling
-
Our high-quality cost-effectiveness models can be used for submission purposes to demonstrate value for money and gain national reimbursement recommendations in the UK, North America, Australia, Canada, Sweden, The Netherlands …..
-
A cost-effectiveness model also generates and demonstrates the economic value messages that will form a key component of the product value story to ensure the product’s market access and adoption.
-
We can develop a full range of economic models to estimate the cost of disease, incremental cost-effectiveness ratio, value-based pricing, budget impact, and expected value of perfect information
